ANDA 203435, held by Novast Labs. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 203435 (Leribane), held by Novast Labs, was first approved by FDA on Jun 3, 2016, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 3, 2016 | Original application | Approved | None posted |
| Leribane0.005MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Leribane0.0025MG;0.5MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Feb 16, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 22, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 3, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters